Subscribe to RSS
DOI: 10.1055/s-0043-1770115
Updated Hemodynamic Definition and Classification of Pulmonary Hypertension
![](https://www.thieme-connect.de/media/srccm/202306/lookinside/thumbnails/10-1055-s-0043-1770115_230601-1.jpg)
Abstract
Pulmonary hypertension (PH) is a pathophysiological manifestation of a heterogeneous group of diseases characterized by abnormally elevated pulmonary arterial pressures diagnosed on right heart catheterization. The 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) Guidelines for the diagnosis and treatment of PH provides a new hemodynamic definition to define PH by lowering the threshold of the mean pulmonary artery pressure (mPAP) to 20 mm Hg. Precapillary PH is thus now defined as a mPAP >20 mm Hg together with a normal pulmonary artery wedge pressure (<15 mm Hg) and an increased pulmonary vascular resistance (>2 Wood Units). The ESC/ERS 2022 Guidelines also introduce a revised clinical classification of PH while retaining its previous distinction between the five groups according to the underlying pathophysiology.
Publication History
Article published online:
18 August 2023
© 2023. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Humbert M, Kovacs G, Hoeper MM. et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023; 61 (01) 2200879
- 2 Lau EMT, Giannoulatou E, Celermajer DS, Humbert M. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol 2017; 14 (10) 603-614
- 3 Hoeper MM, Humbert M, Souza R. et al. A global view of pulmonary hypertension. Lancet Respir Med 2016; 4 (04) 306-322
- 4 Chronic cor pulmonale. Report of an expert committee. World Health Organ Tech Rep Ser 1961; 213: 35
- 5 Galiè N, Humbert M, Vachiery JL. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46 (04) 903-975
- 6 Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34 (04) 888-894
- 7 Maron BA, Hess E, Maddox TM. et al. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the Veterans Affairs clinical assessment, reporting, and tracking program. Circulation 2016; 133 (13) 1240-1248
- 8 Douschan P, Kovacs G, Avian A. et al. Mild elevation of pulmonary arterial pressure as a predictor of mortality. Am J Respir Crit Care Med 2018; 197 (04) 509-516
- 9 Simonneau G, Montani D, Celermajer DS. et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53 (01) 1801913
- 10 Xanthouli P, Jordan S, Milde N. et al. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. Ann Rheum Dis 2020; 79 (03) 370-378
- 11 Kovacs G, Zeder K, Rosenstock P. et al. Clinical impact of the new definition of precapillary pulmonary hypertension. Chest 2021; 159 (05) 1995-1997
- 12 Maron BA, Brittain EL, Hess E. et al. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med 2020; 8 (09) 873-884
- 13 Ho JE, Zern EK, Lau ES. et al. Exercise pulmonary hypertension predicts clinical outcomes in patients with dyspnea on effort. J Am Coll Cardiol 2020; 75 (01) 17-26
- 14 Stamm A, Saxer S, Lichtblau M. et al. Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis. Eur Respir J 2016; 48 (06) 1658-1667
- 15 Hasler ED, Müller-Mottet S, Furian M. et al. Pressure-flow during exercise catheterization predicts survival in pulmonary hypertension. Chest 2016; 150 (01) 57-67
- 16 Lewis GD, Murphy RM, Shah RV. et al. Pulmonary vascular response patterns during exercise in left ventricular systolic dysfunction predict exercise capacity and outcomes. Circ Heart Fail 2011; 4 (03) 276-285
- 17 Zeder K, Banfi C, Steinrisser-Allex G. et al. Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review. Eur Respir J 2022; 60 (04) 2103181
- 18 Kovacs G, Olschewski A, Berghold A, Olschewski H. Pulmonary vascular resistances during exercise in normal subjects: a systematic review. Eur Respir J 2012; 39 (02) 319-328
- 19 Zeder K, Avian A, Bachmaier G. et al. Exercise pulmonary resistances predict long-term survival in systemic sclerosis. Chest 2021; 159 (02) 781-790
- 20 Herve P, Lau EM, Sitbon O. et al. Criteria for diagnosis of exercise pulmonary hypertension. Eur Respir J 2015; 46 (03) 728-737
- 21 Eisman AS, Shah RV, Dhakal BP. et al. Pulmonary capillary wedge pressure patterns during exercise predict exercise capacity and incident heart failure. Circ Heart Fail 2018; 11 (05) e004750
- 22 Bentley RF, Barker M, Esfandiari S. et al. Normal and abnormal relationships of pulmonary artery to wedge pressure during exercise. J Am Heart Assoc 2020; 9 (22) e016339
- 23 Hatano S, Strasser T. World Health Organization; . Primary pulmonary hypertension : report on a WHO meeting, Geneva, 15–17 October, 1973. https://apps.who.int/iris/handle/10665/39094
- 24 Sitbon O, Humbert M, Jaïs X. et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111 (23) 3105-3111
- 25 Montani D, Girerd B, Jaïs X. et al. Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. Eur Respir J 2021; 58 (01) 2004229
- 26 Abenhaim L, Moride Y, Brenot F. et al; International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335 (09) 609-616
- 27 Savale L, Chaumais MC, Cottin V. et al. Pulmonary hypertension associated with benfluorex exposure. Eur Respir J 2012; 40 (05) 1164-1172
- 28 Weatherald J, Chaumais MC, Savale L. et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J 2017; 50 (01) 1700217
- 29 Montani D, Lau EM, Descatha A. et al. Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. Eur Respir J 2015; 46 (06) 1721-1731
- 30 Montani D, Lau EM, Dorfmüller P. et al. Pulmonary veno-occlusive disease. Eur Respir J 2016; 47 (05) 1518-1534
- 31 Montani D, Girerd B, Jaïs X. et al. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respir Med 2017; 5 (02) 125-134
- 32 Vachiéry JL, Tedford RJ, Rosenkranz S. et al. Pulmonary hypertension due to left heart disease. Eur Respir J 2019; 53 (01) 1801897
- 33 Delcroix M, Torbicki A, Gopalan D. et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J 2021; 57 (06) 2002828
- 34 Parent F, Bachir D, Inamo J. et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011; 365 (01) 44-53
- 35 Adir Y, Humbert M. Pulmonary hypertension in patients with chronic myeloproliferative disorders. Eur Respir J 2010; 35 (06) 1396-1406
- 36 Bandyopadhyay D, Humbert M. An update on sarcoidosis-associated pulmonary hypertension. Curr Opin Pulm Med 2020; 26 (05) 582-590
- 37 Humbert M, Labrune P, Simonneau G. Severe pulmonary arterial hypertension in type 1 glycogen storage disease. Eur J Pediatr 2002; 161 (1, suppl 1): S93-S96
- 38 Edmonston DL, Parikh KS, Rajagopal S. et al. Pulmonary Hypertension Subtypes and Mortality in CKD. Am J Kidney Dis 2020; 75 (05) 713-724
- 39 Price LC, Seckl MJ, Dorfmüller P, Wort SJ. Tumoral pulmonary hypertension. Eur Respir Rev 2019; 28 (151) 180065
- 40 Seferian A, Steriade A, Jaïs X. et al. Pulmonary hypertension complicating fibrosing mediastinitis. Medicine (Baltimore) 2015; 94 (44) e1800